Abiomed, Inc., a leading player in the medical technology sector, is headquartered in the United States. Founded in 1981, the company has established itself within the medical, precision and optical instruments industry, focusing primarily on heart pump technology and cardiovascular support devices.
Abiomed is renowned for its innovative products, including the Impella heart pump, which offers unique benefits in minimally invasive heart procedures. This cutting-edge technology has positioned the company as a pioneer in the field, significantly enhancing patient outcomes in critical care settings.
With a strong market presence and a commitment to advancing heart recovery solutions, Abiomed continues to achieve notable milestones, solidifying its reputation as a trusted name in cardiovascular care.
+35 vs industry average
Abiomed, Inc.’s score of 62 is higher than 76% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Abiomed, Inc.?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Medical Device Manufacturing has typical carbon intensity
Industry performance
The Medical Device Manufacturing industry has reduced its overall emissions by 32% since 2018
Reported emissions
No reported emissions data is available for Abiomed, Inc. yet.
Abiomed, Inc.'s reported carbon emissions
Abiomed, Inc., headquartered in the US and operating within the Medical, precision and optical instruments, watches and clocks (33) industry, has established significant climate commitments through its parent company, Johnson & Johnson.
While specific, independently reported absolute emissions figures for Abiomed, Inc. are not available in the provided data, the company's climate strategy is driven by targets set via the Science Based Targets initiative (SBTi) through Johnson & Johnson. These commitments aim to align with a 1.5°C warming pathway.
Key reduction targets include:
- Scope 1 Emissions: A commitment to maintain zero scope 1 emissions through 2034.
- Scope 2 Emissions: A pledge to reduce absolute scope 2 greenhouse gas emissions by 58.8% by 2034, using a 2025 base year.
- Scope 3 Emissions: A commitment to measure and reduce scope 3 emissions.
These targets were approved for A-BIO (which cascades up to Abiomed, Inc. through its relationship with Johnson & Johnson) using a streamlined validation route appropriate for Small and Medium-sized Enterprises (SMEs).
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Abiomed, Inc.’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Abiomed, Inc. yet.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Climate initiatives

Science Based Targets Initiative
Inherited from Johnson & Johnson
Carbon Disclosure Project
Inherited from Johnson & JohnsonThe Climate Pledge
UN Global Compact Climate Champions initiative
RE 100
Inherited from Johnson & JohnsonClimate Action 100
Emissions comparison with industry peers
View similar organisationsNo peer comparison is available for Abiomed, Inc. yet.
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project